Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.

This study shows the limitations of a self-regulatory system around industry disclosure of spending. We advocate for robust regulatory systems, such as legislation, to promote mandatory long-lasting public transparency.